CD74

Overview

CD74 is a classical MHC class II-associated chaperone protein that plays critical roles in antigen presentation and immune regulation. Traditionally understood as an invariant chain involved in MHC-II antigen processing, CD74 has emerged as a multifunctional immune molecule with direct signaling capacity through its interaction with macrophage migration inhibitory factor (MIF). This binding initiates the MIF-CD74 axis, a pathway that coordinates innate immune responses and has been implicated in both protective and pathogenic immune processes across multiple tissues and disease contexts. Beyond its classical role in adaptive immunity, CD74 is now recognized as a direct mediator of immune cell activation, inflammation, and disease progression in neurological, cardiovascular, renal, and oncological conditions.

Role in Recent Research

Recent investigations have significantly expanded the understanding of CD74 from a passive antigen-presentation marker to an active driver of disease pathogenesis across multiple organ systems.

In neuroinflammatory and brain metastasis contexts, CD74 has emerged as a critical regulator of myeloid cell function. Studies examining MIF-induced CD74+ microglia and macrophages demonstrated their central role in promoting brain metastasis progression and contributing to pathology across multiple central nervous system disorders. Rather than functioning solely as an indicator of antigen presentation, CD74 was redefined as a key component of a brain-induced, disease-promoting myeloid program activated through MIF-CD74 signaling. This pathway creates a brain-specific immune vulnerability, particularly relevant to metastatic disease and neurological disorders, with implications for therapeutic intervention through MIF-CD74 inhibitors.

In cardiovascular pathology, hypoxia was shown to induce adaptive lymphangiogenesis through coordinated signaling involving CD74 and VEGFR3, demonstrating its role in pulmonary hypertension modulation. This finding suggests CD74 participates in hypoxia-responsive vascular remodeling, expanding its functional repertoire beyond immune regulation.

CD74 signaling cascades have also been implicated in renal inflammatory disease. Investigation of uromodulin variants revealed that pathogenic mutations activate the amyloid precursor protein (APP)-CD74 axis, which mediates crosstalk between renal tubular cells and macrophages, promoting macrophage pyroptosis and driving renal inflammation in hereditary kidney disease. This mechanism highlights how CD74 integrates signals from multiple protein partners to coordinate cellular responses in disease states.

In oncology, CD74 has been identified as an oncogenic driver in breast cancer. Functional studies employing CRISPR-Cas methods and molecular silencing approaches demonstrated that CD74 suppression significantly reduces cancer cell proliferation, migration, and tumor growth in vivo. These findings position CD74 as a therapeutic target for cancer progression alongside other oncogenic immune drivers including NF-κB pathway components.

These recent investigations collectively demonstrate that CD74 functions as a molecular hub integrating immune activation, inflammatory signaling, and tissue-specific pathology. Therapeutic strategies targeting CD74—whether through MIF-CD74 inhibitors or direct receptor antagonism—represent promising approaches for managing inflammatory, neurological, cardiovascular, and malignant diseases associated with aberrant CD74 signaling.

Key Publications

NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42233213)
Jun Biomedical publication details. (PubMed Database, 2026, PMID 41874311)
Jun Biomedical publication details. (PubMed Database, 2026, PMID 42388022)
Jun Biomedical publication details. (PubMed Database, 2026, PMID 41912015)
Jun Biomedical publication details. (PubMed Database, 2026, PMID 42049740)
Jun Biomedical publication details. (PubMed Database, 2026, PMID 41920337)